Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma.

Chan AT, Zauber AG, Hsu M, Breazna A, Hunter DJ, Rosenstein RB, Eagle CJ, Hawk ET, Bertagnolli MM.

Gastroenterology. 2009 Jun;136(7):2127-2136.e1. doi: 10.1053/j.gastro.2009.02.045.

2.

CYP2C9 variants increase risk of colorectal adenoma recurrence and modify associations with smoking but not aspirin treatment.

Barry EL, Poole EM, Baron JA, Makar KW, Mott LA, Sandler RS, Ahnen DJ, Bresalier RS, McKeown-Eyssen GE, Ulrich CM.

Cancer Causes Control. 2013 Jan;24(1):47-54. doi: 10.1007/s10552-012-0088-6.

3.

The influence of UGT1A6 variants and aspirin use in a randomized trial of celecoxib for prevention of colorectal adenoma.

Chan AT, Hsu M, Zauber AG, Hawk ET, Bertagnolli MM.

Cancer Prev Res (Phila). 2012 Jan;5(1):61-72. doi: 10.1158/1940-6207.CAPR-11-0337.

4.

Celecoxib for the prevention of sporadic colorectal adenomas.

Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET; APC Study Investigators..

N Engl J Med. 2006 Aug 31;355(9):873-84.

5.

Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study.

Kraus S, Hummler S, Toriola AT, Poole EM, Scherer D, Kotzmann J, Makar KW, Kazanov D, Galazan L, Naumov I, Coghill AE, Duggan D, Gigic B, Arber N, Ulrich CM.

Pharmacogenet Genomics. 2013 Aug;23(8):428-37. doi: 10.1097/FPC.0b013e3283631784.

6.

Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial.

Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Breazna A, Kim K, Tang J, Rosenstein RB, Umar A, Bagheri D, Collins NT, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Hawk ET; Adenoma Prevention with Celecoxib Study Investigators..

Cancer Prev Res (Phila). 2009 Apr;2(4):310-21. doi: 10.1158/1940-6207.CAPR-08-0206.

7.

C-reactive protein and risk of colorectal adenoma according to celecoxib treatment.

Chan AT, Sima CS, Zauber AG, Ridker PM, Hawk ET, Bertagnolli MM.

Cancer Prev Res (Phila). 2011 Aug;4(8):1172-80. doi: 10.1158/1940-6207.CAPR-10-0403.

8.

Celecoxib for the prevention of colorectal adenomatous polyps.

Arber N, Eagle CJ, Spicak J, Rácz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B; PreSAP Trial Investigators..

N Engl J Med. 2006 Aug 31;355(9):885-95.

9.

Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas.

Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, Levin B, Eagle C, Hawk E, Lechuga M, Zauber AG, Bertagnolli MM, Arber N, Wittes J; APC and PreSAP Trial Investigators..

Circulation. 2006 Sep 5;114(10):1028-35.

10.

Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib.

Brenner SS, Herrlinger C, Dilger K, Mürdter TE, Hofmann U, Marx C, Klotz U.

Clin Pharmacokinet. 2003;42(3):283-92.

PMID:
12603175
11.

A prospective study of genetic polymorphisms in the cytochrome P-450 2C9 enzyme and the risk for distal colorectal adenoma.

Chan AT, Tranah GJ, Giovannucci EL, Hunter DJ, Fuchs CS.

Clin Gastroenterol Hepatol. 2004 Aug;2(8):704-12.

PMID:
15290664
12.

Association between the CYP2C9 polymorphism and the drug metabolism phenotype.

Topić E, Stefanović M, Samardzija M.

Clin Chem Lab Med. 2004 Jan;42(1):72-8.

PMID:
15061384
13.

Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites.

Kirchheiner J, Störmer E, Meisel C, Steinbach N, Roots I, Brockmöller J.

Pharmacogenetics. 2003 Aug;13(8):473-80.

PMID:
12893985
14.

Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9.

Loebstein R, Vecsler M, Kurnik D, Austerweil N, Gak E, Halkin H, Almog S.

Clin Pharmacol Ther. 2005 May;77(5):365-72.

PMID:
15900282
15.

Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial.

Bertagnolli MM, Hsu M, Hawk ET, Eagle CJ, Zauber AG; Adenoma Prevention with Celecoxib (APC) Study Investigators..

Cancer Prev Res (Phila). 2010 May;3(5):588-96. doi: 10.1158/1940-6207.CAPR-09-0271.

16.

Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study.

Wang J, Carvajal-Carmona LG, Chu JH, Zauber AG; APC Trial Collaborators., Kubo M, Matsuda K, Dunlop M, Houlston RS, Sieber O, Lipton L, Gibbs P, Martin NG, Montgomery GW, Young J, Baird PN, Ratain MJ, Nakamura Y, Weiss ST, Tomlinson I, Bertagnolli MM.

Clin Cancer Res. 2013 Dec 1;19(23):6430-7. doi: 10.1158/1078-0432.CCR-13-0550.

17.

Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms.

Pilotto A, Seripa D, Franceschi M, Scarcelli C, Colaizzo D, Grandone E, Niro V, Andriulli A, Leandro G, Di Mario F, Dallapiccola B.

Gastroenterology. 2007 Aug;133(2):465-71.

PMID:
17681167
18.

Genetic variants of UGT1A6 influence risk of colorectal adenoma recurrence.

Hubner RA, Muir KR, Liu JF, Logan RF, Grainge M, Armitage N, Shepherd V, Popat S, Houlston RS; United Kingdom Colorectal Adenoma Prevention Consortium..

Clin Cancer Res. 2006 Nov 1;12(21):6585-9.

19.

Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.

Carlquist JF, Horne BD, Muhlestein JB, Lappé DL, Whiting BM, Kolek MJ, Clarke JL, James BC, Anderson JL.

J Thromb Thrombolysis. 2006 Dec;22(3):191-7.

PMID:
17111199
20.

Evaluation of the relationship between polymorphisms in CYP2C8 and CYP2C9 and the pharmacokinetics of celecoxib.

Prieto-Pérez R, Ochoa D, Cabaleiro T, Román M, Sánchez-Rojas SD, Talegón M, Abad-Santos F.

J Clin Pharmacol. 2013 Dec;53(12):1261-7. doi: 10.1002/jcph.169.

PMID:
23996211
Items per page

Supplemental Content

Support Center